Oil prices steady near 1-mth high on US-Iran sanctions; OPEC+ meeting awaited
Precigen Inc (PGEN) stock has reached a new 52-week high, with its price hitting $4.83. According to InvestingPro analysis, the company, now valued at $1.41 billion, appears overvalued at current levels, with analysts setting price targets between $8.00 and $8.50. This milestone reflects a significant upward trend for the company, marking a 347.17% increase over the past year. The biotechnology firm has seen its stock price soar, driven by investor optimism and positive developments within the company. With a healthy current ratio of 2.71 and strong momentum across multiple timeframes, this impressive one-year change highlights Precigen’s strong performance in the market, as it continues to capture investor interest and confidence. InvestingPro subscribers can access 12 additional technical indicators and detailed financial metrics to make more informed investment decisions.
In other recent news, Precigen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval for PAPZIMEOS, a treatment for adults with recurrent respiratory papillomatosis (RRP). This approval makes PAPZIMEOS the first and only FDA-approved therapy for this condition. Additionally, H.C. Wainwright reiterated its Buy rating on Precigen, setting a price target of $8.50 following the FDA’s decision. The wholesale acquisition cost for a full treatment cycle of PAPZIMEOS is set at $460,000. Furthermore, Citizens JMP raised its price target for Precigen to $8, maintaining a Market Outperform rating. In another development, Precigen has entered into a commercial supply agreement with Catalent Maryland, Inc. for the manufacturing of PAPZIMEOS, effective August 2025. This agreement requires Precigen to use Catalent exclusively for manufacturing services. Cantor Fitzgerald also reiterated its Overweight rating on Precigen, maintaining a positive outlook despite recent stock volatility. These developments highlight significant progress and strategic partnerships for Precigen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.